NCT06850766View on ClinicalTrials.gov

The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2031

Conditions
IDH-Wildtype GlioblastomaGlioblastoma (GBM)
Interventions
OTHER

Morning administration of TMZ

Administration of TMZ within 2 hours of waking

OTHER

Evening administration of TMZ

Administration of TMZ within 2 hours of bedtime

Trial Locations (2)

N6A 5W9

NOT_YET_RECRUITING

London Health Sciences Centre, London

K1H 8L6

RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

Sponsors
All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

lead

Ottawa Hospital Research Institute

OTHER